Gene & Cell Therapy Development
Vector design, therapy manufacturing.
What it does
LiveVector design, therapy manufacturing.
The traditional flow
Liveflowchart TD
A[Delivery vector designed for target gene] --> B[Vector manufactured under GMP]
B --> C[Patient cells collected if autologous]
C --> D[Therapy manufactured per-patient or per-batch]
D --> E[Therapy shipped to treatment site]Where it breaks
LiveMain pain pointPer-patient manufacturing (autologous therapies) is manually coordinated and logistically complex.
Stage 2: The What-If redesign
Tools in use today
Coming soonThe systems, spreadsheets and handoffs this process relies on in a typical organization.
Pain points in depth
Coming soonEach pain point broken down: where it happens, who feels it, and what it costs in time, errors or risk.
Today's critical user journey
Coming soonWho touches the process, in what order, and where delays and errors creep in.
The What-If agent ecosystem
Coming soonA named roster of agents, each with one responsibility, plus the orchestration diagram and the human checkpoints.
The new critical user journey
Coming soonThe same journey redesigned around the agents: what changes for each person and where they still step in.
Before and after
Coming soonA side-by-side comparison of the traditional flow and the agentic redesign.
How each pain point gets solved
Coming soonEvery pain point mapped to the agent or checkpoint that removes it.
Business outcomes
Coming soonThe generic business outcomes this redesign could drive. Any figures are illustrative estimates, never measured results.